NewsAI-assisted

Cormica Expands European Presence with Acquisition of Zwisler Laboratorium

Strategic acquisition in Germany enhances Cormica’s capabilities and market reach in Europe.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Jan 21, 2025Updated Jun 26, 2025 · 2 min read
Cormica Expands European Presence with Acquisition of Zwisler Laboratorium
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Cormica, a global leader in life sciences testing and consulting, has successfully acquired Zwisler Laboratorium, a premier laboratory services provider based in Reichenau, Germany. This acquisition marks a significant milestone for Cormica, as it represents the company’s first foray into the German market, a key component of its strategy to expand across Europe. With the acquisition, Cormica aims to strengthen its position in high-growth European markets and explore further expansion opportunities in Germany.

Founded in 2001, Zwisler Laboratorium is known for its advanced in-vitro testing services and its expertise in meeting rigorous regulatory standards for pharmaceutical, biotech, medical device, and packaging industries across Europe. The laboratory specializes in services like pyrogen testing, environmental monitoring, reprocessing validation, and microbiological integrity tests. By integrating Zwisler’s cutting-edge technologies and expertise into its portfolio, Cormica enhances its ability to support life science manufacturers, helping them bring critical medical technologies to market quickly and safely. This acquisition complements Cormica's existing operations in the UK and US and positions the company for continued growth in the global life sciences testing market.

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →